Short stay pyeloplasty: variables affecting pain and length of stay.

Short stay pyeloplasty: variables affecting pain and length of stay. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Short stay pyeloplasty: variables affecting pain and length of stay. Abstract Text:

PURPOSE: Pyeloplasty is increasingly performed on a short stay basis. We sought to determine what patient and treatment variables affect postoperative pain and length of stay, and whether an open approach could be considered "minimally invasive." MATERIALS AND METHODS: We performed a retrospective review of patients younger than 10 years who underwent open pyeloplasty between 2001 and 2007. All patients received ketorolac every 6 hours and acetaminophen with codeine as needed. Data extracted from the medical records included morphine and codeine usage, patient age and gender, incision type, operative time, stent usage and outcome data (pain scores and length of stay). Multiple regression analyses were used to determine the association between variables and outcomes. RESULTS: A total of 51 patients met the inclusion criteria. Patient age and gender, operative time and stent usage had no significant correlation with mean or median pain scores. Children who received morphine had significantly higher mean, median and maximum pain scores and length of stay (33 vs 23 hours) than those who did not receive morphine. Multiple regression analyses revealed that morphine usage and dorsal lumbotomy incision were independently associated with higher mean, median and maximum pain scores, and a nephroureteral catheter was correlated with a higher maximum pain score. The only variable associated with length of stay was morphine usage. CONCLUSIONS: Morphine usage was the most significant variable associated with increased pain scores and increased length of stay. Ketorolac and acetaminophen/codeine provide better pain control, and allow children to return home within 24 hours. With mean pain scores less than 1 this series demonstrates that open pyeloplasty can be "minimally invasive."

Short stay pyeloplasty: variables affecting pain and length of stay. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Short stay pyeloplasty: variables affecting pain and length of stay. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Journal of urology

VOLUME: 179

Page Numbers: 1549-52

Journal Abbreviation: J. Urol.

ISSN: 1527-3792

DAY: 4

MONTH: 03

YEAR: 2008

Short stay pyeloplasty: variables affecting pain and length of stay. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 376374

Short stay pyeloplasty: variables affecting pain and length of stay. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Short stay pyeloplasty: variables affecting pain and length of stay. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Short stay pyeloplasty: variables affecting pain and length of stay.

AFFILIATION: Department of Urology, University of California, Davis Children's Hospital and School of Medicine, Sacramento, California 95817, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Urol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Short stay pyeloplasty: variables affecting pain and length of stay Related Publications

• Beta1 integrin expression pattern in transitional urothelium does not allow for efficient stem cell enrichment as in other epithelia.
• Complete bladder duplication presenting as incontinence in an 11-year-old girl.
• Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.
• Cutaneous castleman's disease responds to anti interleukin-6 treatment.
• Development and validation of the fecal incontinence and constipation quality of life measure in children with spina bifida.
• Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials.
• How do we measure hypospadias outcomes?
• Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides.
• Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics.
• Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
• Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
• Non-surgical management of multicystic dysplastic kidney.
• Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
• Short stay pyeloplasty: variables affecting pain and length of stay.
• Studies in target-based treatment.
• The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
• [Vinca rosea in the treatment of hemoblastoses and similar clinical pictures.]